Clinical trial NCT01016483 (phase 1/phase 2, status: completed)
Conditions: pancreatic adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: pimasertib, gemcitabine, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subject has provided signed informed consent. Fully understands requirements of the
             trial and willing to comply with all trial visits and assessments.

          2. Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas
             and availability of tumor sample.

          3. Evidence of disease (not necessarily measurable disease). Complete tumor assessment
             including chest X ray, CT scan of abdomen and other scans as necessary to document all
             sites of disease performed within 28 days prior to trial entry/randomization.

          4. Age ≥ 18 years.

          5. Women of childbearing potential must have a negative blood pregnancy test at the
             screening visit. For the purposes of this trial, women of childbearing potential is
             defined as: "All female subjects after puberty unless they are post-menopausal for at
             least two years, are surgically sterile or are sexually inactive."

          6. Female subjects of childbearing potential and male subjects with female partners of
             childbearing potential must be willing to avoid pregnancy by using an adequate method
             of contraception for 2 weeks prior to screening, during and four weeks after the last
             dose of trial medication. Adequate contraception is defined as two barrier methods, or
             one barrier method with a spermicide, or intrauterine device. The use of hormonal
             contraceptives should be avoided in female subjects of childbearing potential due to a
             possible drug-drug interaction.

        Exclusion Criteria:

          1. Bone marrow impairment as evidenced by hemoglobin less (<) 9.0 gram per deciliter
             (g/dL), neutrophil count < 1.5 x 10^9/ liter (L), platelets < 100 x 10^9/L.

          2. Renal impairment as evidenced by serum creatinine > 1.5 x upper limit of normal (ULN),
             and/or calculated creatinine clearance < 60 mL/min.

          3. Liver function abnormality as defined by total bilirubin > 1.5 x ULN, or aspartate
             aminotransferase/ alanine aminotransferase (AST/ALT) > 2.5 x ULN, for subjects with
             liver involvement AST/ALT > 5 x ULN.

          4. Serum calcium > 1 x ULN.

          5. History of central nervous system (CNS) metastases, unless subject has been previously
             treated for CNS metastases, is stable by CT scan without evidence of cerebral edema,
             and has no requirements for corticosteroids or anticonvulsants.

          6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) greater than 1.

          7. Significant cardiac conduction abnormalities, including QT interval corrected for
             heart rate (QTc) prolongation of > 480 milliseconds (ms) and/or pacemaker.

          8. Retinal degenerative disease (hereditary retinal degeneration or age-related macular
             degeneration), history of uveitis or history of retinal vein occlusion.